October 2012

Life sciences


Medicago and Philip Morris Products Sign Commercial Agreement for Influenza Vaccines in China

Medicago and Philip Morris Products Sign Commercial Agreement for Influenza Vaccines in China

Medicago announced the signing of a licensing agreement with Philip Morris Products SA, a subsidiary of Philip Morris International, the leading international tobacco company with products sold in approximately 180 countries. Under the agreement, Medicago grants PMP an exclusive license to develop, commercialize and manufacture Medicago's pandemic and seasonal influenza vaccines for China. In addition, Medicago has signed an exclusive, worldwide license for a portfolio of plant-based protein development technologies from PMP.


Blue Light Helps Tired Workers and Motorists Regulate Their Internal Clocks

Blue Light Helps Tired Workers and Motorists Regulate Their Internal Clocks

Researchers at Université Laval have developed a blue light to help bleary eyed shift workers regulate their internal clocks and get the sleep they need when they need it. One-third of Canada's workforce - approximately 6.5 million people - work shifts that keep them awake at night and require them to sleep during the day. From police officers and firefighters to manufacturers and truck drivers, many Canadians rely on an assortment of coffee, energy drinks and medication to keep themselves alert at night and sleep when the sun is shining.


Aeterna Zentaris Granted Patent in the U.S. for Diagnostic Test for Adult Growth Hormone Deficiency

Aeterna Zentaris announced that the United States Patent and Trademark Office has granted a patent for the use of its oral ghrelin agonist, AEZS-130 as a diagnostic test for adult growth hormone deficiency. Filed on February 19, 2007, the patent titled, "Methods and Kits to Diagnose Growth Hormone Deficiency by Oral Administration of EP1572 or EP1573 Compounds", became effective as of June 5, 2012, and will expire on October 12, 2027. 


TSO3 and GETINGE sign letter of intent for global distribution agreement

TSO3 and GETINGE sign letter of intent for global distribution agreement

TSO3  is pleased to announce that it has signed today a Letter of Intent with a division of worldwide GETINGE GROUP headquartered in Sweden, for the purpose of completing a global channel partner agreement for its new generation STERIZONE®Sterilizers.


IDRI and Medicago Announce FDA Authorization to Initiate a Phase 1 Clinical Trial for an H5N1 Vaccine with GLA Adjuvant

The Infectious Disease Research Institute, a Seattle-based non-profit research organization that is a leading developer of adjuvants used in vaccines combating infectious disease, and Medicago announce that they have been cleared by the U.S. Food and Drug Administration to initiate a Phase 1 clinical trial for an H5N1 Avian Influenza VLP vaccine candidate. This is an important step toward development of an influenza vaccine that could be rapidly and widely administered in case of a pandemic flu outbreak. The trial is focused on evaluating the safety and immunogenicity of the H5N1 vaccine, combined with IDRI's Glucopyranosyl Lipid A adjuvant.


Aeterna Zentaris Granted Patent by European Patent Office

Aeterna Zentaris today announced that the European Patent Office has granted a patent for the use of the ghrelin agonist, AEZS-130, related to methods and kits for use in relation to the diagnosis of growth hormone deficiency in a human or animal subject. Filed on February 19, 2007, the patent titled, "Methods and Kits to Diagnose Growth Hormone Deficiency", was effective as of September 19, 2012, following its announcement in the European Patent Bulletin, and will expire on February 19, 2027. A similar patent has already been granted in the U.S.


Medicago and Cellectis Successfully Achieve First Step in Research Collaboration

Medicago and Cellectis plant sciences, a US-based subsidiary of Cellectis Group, the specialist in genome engineering, today announced the successful completion of the first step in their research collaboration to improve therapeutic proteins produced in tobacco plants. As part of an ongoing effort in the development biosimilar protein therapeutics from tobacco plants, Medicago is partnering with Cellectis to modify the glycosylation of biosimilar product candidates.  A biosimilar product is a therapeutic protein, which is similar in terms of quality, safety and efficacy to an already approved and marketed biotherapeutic product. Glycosylation is the addition of sugar molecules to proteins. Modifying the glycosylation of a protein can optimize the efficacy and other characteristics such as solubility, therapeutic half-life, and tissue distribution.


TELUS acquires KinLogix, Quebec's fastest-growing cloud-based Electronic Medical Record provider

Reinforcing its commitment to provide the best healthcare information technology solutions in Canada, TELUS announced today the acquisition of privately-held KinLogix, the largest provider of cloud-based Electronic Medical Records (EMR) in Quebec. Financial terms of the agreement were not disclosed. This strategic acquisition strengthens TELUS Health's leadership in the EMR market and furthers its efforts to accelerate the adoption of EMR solutions to continue to improve Canada's health system, and most importantly, deliver better health outcomes for patients. The KinLogix EMR is a cloud-based solution used in medical clinics that captures, organizes, and displays critical patient data in one integrated patient record, while streamlining administrative tasks, improving care delivery and further enriching the patient-physician encounter.